Phytopharmacological evaluation of Byesukar for hypoglycaemic activity and its effect on lipid profile and hepatic enzymes of glucose metabolism in diabetic rats.
Many anti-diabetic herbal preparations have been recommended in alternative systems of medicine for the treatment of diabetes. No systematic study has been done on the anti-diabetic efficacy of Byesukar, a polyherbal formulation to treat diabetes. The anti-diabetic efficacy of byesukar ethanol extract was evaluated in an animal model of diabetes induced by alloxan. Male Wistar rats were divided in to four groups. Group 1 was normal control group; group 2 and 3 received alloxan. After inducing experimental diabetes group 2 served as diabetic control; group 3 received byesukar (500 mg/kg body weight) orally for 30 consecutive days. Group 4 were normal rats which received byesukar extract alone. The effect of byesukar on glucose level in diabetic rats was studied and the level of glucose metabolizing enzymes (Hexokinase, glucose-6-phosphatase and fructose 1, 6-bisphosphatase) in the liver and kidney were estimated. The effect of byesukar on the serum and tissue lipid profile (Cholesterol, triglycerides, phospholipids and free fatty acids) were also estimated in diabetic rats. Our results indicate that treatment with byesukar resulted in significant reduction of blood glucose, tissue glucose-6-phosphatase and fructose 1, 6- bisphosphatase activity. The decreased tissue hexokinase activity in diabetes state was found to be significantly increased by byesukar treatment. Also the byesukar treated diabetic rats showed a significant decrease in the tissue lipid profile compared to the diabetic rats. In conclusion the decreased blood glucose accompanied with decreased lipid profile and changes in the activities of the glucose metabolizing enzymes shows the antidiabetic effect of byesukar.
Guruvayoorappan
C
C
Department of Bio-Technology, Karunya University, Coimbatore-641 114. gurukarunya@gmail.com
Sudha
G
G
D000818:Animals; D001786:Blood Glucose / Q000032:analysis* / Q000187:drug effects; D002366:Cassia; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism*; D006597:Fructose-Bisphosphatase / Q000378:metabolism; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D006593:Hexokinase / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D019660:Malvaceae; D008517:Phytotherapy; D028321:Plant Preparations / Q000494:pharmacology*; D018514:Plant Structures; D051381:Rats; D017208:Rats, Wistar; D027842:Syzygium
D001786:Blood Glucose; C538764:Byesukar; D007004:Hypoglycemic Agents; D028321:Plant Preparations; D006593:Hexokinase; D006597:Fructose-Bisphosphatase; D005952:Glucose-6-Phosphatase